Home › Companies › INGENIA Therapeutics

INGENIA Therapeutics

인제니아테라퓨틱스 · 950260 · KOSDAQ

Filings, last 12 months

Supply contracts

Insider reports

Share & bond issues

At a glance

INGENIA Therapeutics filed 21 disclosures in the last 12 months, including 6 insider and 2 5% holder. The most recent key filing was on Sep 29: A major holder's stake fell from 76.80% to 74.60%.

Of 2 recent 5%+ holder reports, 1 raised and 1 cut a stake; the largest stake reported was 76.80% on Aug 25.

Financial summary

2026 H1

Revenue -

Op. profit -₩5M

Debt/equity 67%

RevenueOperating profitOperating lossConsolidated where available · from periodic reports

5%+ holder reports

9/29Stake 74.60%-2.20pp

8/25Stake 76.80%+76.80pp

Key filings

9/295% holderA major holder's stake fell from 76.80% to 74.60%.74.60%

8/25InsiderAmendedOther change10%+ shareholder's holding rose by 6,012,807 sh (new report).+6,012,807 sh

8/25InsiderOther change10%+ shareholder's holding rose by 9,731,629 sh (new report).+9,731,629 sh

8/25InsiderOther change10%+ shareholder's holding rose by 6,012,807 sh (new report).+6,012,807 sh

8/25InsiderOther changePresident's holding rose by 164,389 sh (new report).+164,389 sh

8/25InsiderOther changePresident's holding rose by 1,014,892 sh (new report).+1,014,892 sh

8/25InsiderOther changePresident's holding rose by 1,285,879 sh (new report).+1,285,879 sh

8/25InsiderOther changeCEO's holding rose by 10,149,093 sh (new report).+10,149,093 sh

8/255% holderNew 5%A major holder's stake rose from 0.00% to 76.80% (new report).76.80%

Other filings

10/27Filing

9/30Filing

9/28Filing

8/19Half-year report

8/4Securities issuance results

7/28Prospectus

7/28Registration statement

7/24Prospectus

7/21Registration statement

7/1Registration statement

6/10Registration statement

Links open the original filing on DART, in Korean.